OPN-6602 not checked

Opna Bio LLC

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“orally active, small molecule inhibitor of EP300 and CBP bromodomain; dosed daily”In the company’s words, NCT06433947 on ClinicalTrials.gov
Tested for
Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Main trialPhase 1
“Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.”In the company’s words, NCT06433947 on ClinicalTrials.gov

Other drugs for Relapsed Multiple Myeloma

All 133 drugs for Relapsed Multiple Myeloma

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting Dec 2027 Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow OPN-6602

Following is part of Solo: you see every change to OPN-6602 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in